Does Baycol (cerivastatin) cause side effects?
Baycol (cerivastatin) is an HMGCoA reductase inhibitor (a “statin”) that lowers cholesterol in the blood by blocking the enzyme in the liver that is responsible for producing cholesterol. It lowers total cholesterol as well as the LDL subfraction of cholesterol in the blood.
LDL cholesterol is believed to be the "bad" cholesterol that is primarily responsible for the development of coronary artery disease. Lowering LDL cholesterol levels retards and may even reverse coronary artery disease. The brand name Baycol is discontinued in the U.S.
Common side effects of Baycol include
Serious side effects of Baycol include
- persistently abnormal liver tests during treatment, and
- muscle damage due to inflammation (myositis) that can lead to kidney failure (rare).
Drug interactions of Baycol include cyclosporine, gemfibrozil, erythromycin, itraconazole, and nicotinic acid, because the risk of muscle damage (see below) is increased when they are given at the same time.
It is unknown if Baycol causes harm to the fetus if taken during pregnancy. Baycol may be used in pregnancy if the physician feels that its benefits outweigh its potential risks.
What are the important side effects of Baycol (cerivastatin)?
- Cerivastatin generally is well-tolerated, and side effects are rare.
- Minor side effects include constipation, diarrhea, fatigue, gas, heartburn, nasal congestion, and headache.
- Cerivastatin should be used with caution in patients with alcoholic or other liver diseases.
- Persistently abnormal liver tests during treatment are rare but may require discontinuation of the medication.
- Rare cases of muscle damage due to inflammation (myositis) have been reported with other drugs in the same class as cerivastatin, and is presumed also to occur with cerivastatin as well. (Muscle inflammation causes the release of muscle protein, myoglobin, into the blood where it is carried to the kidneys and leads to kidney failure.)
Baycol (cerivastatin) side effects list for healthcare professionals
Cerivastatin sodium has been evaluated for adverse events in more than 5,000 patients worldwide. In the U.S. placebo-controlled clinical studies, discontinuations due to adverse events occurred in 3.1% of cerivastatin sodium treated patients and in 2.0% of patients treated with placebo. Adverse reactions have usually been mild and transient.
Clinical Adverse Experiences
Adverse experiences occurring with a frequency ≥ 2% for marketed doses of cerivastatin sodium, regardless of causality assessment, in U.S. placebo-controlled clinical studies, are shown in Table 5 below:
Table 5: Adverse Experiences occurring in ≥ 2% Patients
in U.S. Placebo Controlled Clinical Studies
|Adverse Event|| Baycol
(n = 2231)
(n = 702)
The following effects have been reported with drugs in this class; not all effects listed below have necessarily been associated with cerivastatin therapy.
- Skeletal: myopathy, muscle cramps, rhabdomyolysis, arthralgias, myalgia.
- Neurological: dysfunction of certain cranial nerves (including alteration of taste, impairment of extra-ocular movement, facial paresis), tremor, dizziness, memory loss, vertigo, paresthesia, peripheral neuropathy, peripheral nerve palsy, anxiety, insomnia, depression, psychic disturbances.
- Hypersensitivity Reactions: An apparent hypersensitivity syndrome has been reported that included one or more of the following features: anaphylaxis, angioedema, lupus erythematosus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.
- Gastrointestinal: pancreatitis, hepatitis, including chronic active hepatitis, cholestatic jaundice, fatty change in liver, cirrhosis, fulminant hepatic necrosis, and hepatoma; anorexia, vomiting.
- Skin: alopecia, pruritus. A variety of skin changes, (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails), have been reported. Reproductive: gynecomastia, loss of libido, erectile dysfunction.
- Eye: progression of cataracts (lens opacities), ophthalmoplegia.
- Laboratory Abnormalities: elevated transaminases, creatine kinase, alkaline phosphatase, γ-glutamyl transpeptidase, and bilirubin; thyroid function abnormalities.
Post-Marketing Adverse Event Reports
The following events have been reported since market introduction. While these events were generally associated with the use of Baycol (cerivastatin (removed from market 8/2001)) , a casual relationship to the use of Baycol (cerivastatin (removed from market 8/2001)) cannot be readily determined due to the spontaneous nature of reporting of medical events, and the lack of controls.
- Body as a Whole: Asthenia, fever, headache, anorexia, abdominal pain, epistaxis, edema.
- Cardiovascular System: Hypertension, angina pectoris.
- Digestive System: Colitis, constipation, diarrhea, duodenal ulcer, dyspepsia, flatulance, gastrointestinal disorder, gastrointestinal hemorrhage, hepatitis, nausea.
- Hemolytic and Lymphatic System: Anemia, leukopenia.
- Hypersensitivity Reaction: Allergic reaction, anaphylactoid reaction, angioedema, urticaria.
- Nervous System: Paralysis, somnolence.
- Musculoskeletal System: Myalgia, myasthenia, myopathy, myositis, rhabdomyolysis, hypertonia, hyperkinesia.
- Respiratory System: Cough increase.
- Urogenital System: Acute renal failure secondary to myoglobinuria.
- Special Senses: Cataract specified, visual disturbance, blurred vision.
- Amylase increase,
- elevated transaminases,
- laboratory tests abnormal,
- kidney function abnormal,
- creatine phosphokinase increase.
In studies where cerivastatin sodium has been administered concomitantly with cholestyramine, no adverse reactions unique to this combination or in addition to those previously reported for this class of drugs were reported.
- Myopathy and rhabdomyolysis (with or without acute renal failure) have been reported when HMG-CoA reductase inhibitors are used in combination with immunosuppressive drugs, fibric acid derivatives, erythromycin, azole antifungals or lipid-lowering doses of nicotinic acid.
- Concomitant therapy with HMG-CoA reductase inhibitors and these agents is generally not recommended. Concurrent treatment with gemfibrozil is contraindicated.
What drugs interact with Baycol (cerivastatin)?
- Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid), Erythromycin, Azole Antifungals: see prescribing information.
- ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.
- CIMETIDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.
- CHOLESTYRAMINE: The influence of the bile-acid-sequestering agent cholestyramine on the pharmacokinetics of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies. In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone. However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone. Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.
- DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium. Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.
- WARFARIN: Co-administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo. The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium. Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.
- ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
- ITRACONAZOLE: In hypercholesterolemic patients, following a 0.3 mg dose of cerivastatin, steady-state cerivastatin AUC and Cmax increased 38% and 12%, respectively after 10 days with co-administration of 200 mg itraconazole, a potent inhibitor of cytochrome P450 3A4. Cerivastatin half-life was approximately 5 hours (a 64% increase) following co-administration with itraconazole, which would not lead to accumulation of cerivastatin upon multiple dosing. The administration of 0.3 mg of cerivastatin concomitantly with itraconazole has no effect on itraconazole pharmacokinetics.
- In a single dose crossover study using 0.8 mg cerivastatin, the AUC and Cmax of cerivastatin were increased 27% and 25% respectively during concomitant itraconazole treatment.
- OMEPRAZOLE: There were no changes in the pharmacokinetic parameters of either cerivastatin or its major active metabolites, or of omeprazole in healthy young males given single 0.3 mg oral doses of cerivastatin alone or on the fifth day of a five-day omeprazole 20 mg daily pre-treatment.
- GEMFIBROZIL: The potential for clinically relevant interaction between gemfibrozil and cerivastatin has not been assessed in clinical trials. However, during postmarketing surveillance, patients on cerivastatin who experienced rhabdomyolysis and associated renal failure, were in most cases also taking gemfibrozil.
- CYCLOSPORINE: The single dose pharmacokinetics of 0.2 mg of cerivastatin in healthy subjects was compared to the pharmacokinetics of single and multiple doses in renal transplant patients who were at steady-state with respect to cyclosporine. Cyclosporine levels were unaffected by cerivastatin. Plasma concentrations of cerivastatin and its metabolites increased 3- to 5-fold with no change in its elimination. No cerivastatin accumulation occurred with multiple dosing.
- Endocrine Function: HMG-CoA reductase inhibitors interfere with cholesterol synthesis and lower cholesterol levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. Clinical studies have shown that cerivastatin sodium has no adverse effect on sperm production and does not reduce basal plasma cortisol concentration, impair adrenal reserve or have an adverse effect on thyroid metabolism as assessed by TSH. Results of clinical trials with drugs in this class have been inconsistent with regard to drug effect on basal and reserve steroid levels. The effects of HMG-CoA reductase inhibitors on male fertility have not been studied in adequate numbers of male patients. The effects, if any, on the pituitary-gonadal axis in pre-menopausal women are unknown.
- Patients treated with cerivastatin sodium who develop clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs that may decrease the levels or activity of endogenous steroid hormones, e.g., ketoconazole, spironolactone, or cimetidine.
- CNS and other Toxicities: Chronic administration of cerivastatin to rodent and non-rodent species demonstrated the principal toxicologic targets and effects observed with other HMG-CoA reductase inhibitors: Hemorrhage and edema in multiple organs and tissues including CNS (dogs); cataracts (dogs); degeneration of muscle fibers (dogs, rats, and mice); hyperkeratosis in the non-glandular stomach (rats and mice, this organ has no human equivalent); liver lesions (dogs, rats, and mice).
- CNS lesions were characterized by multifocal bleeding with fibrinoid degeneration of vessel walls in the plexus chorioideus of the brain stem and in the ciliary body of the eye at 0.1 mg/kg/day in the dog. This dose resulted in plasma levels of cerivastatin (Cmax, measured as free drug), that were about 17 times higher than the mean values in humans taking 0.8 mg/day. No CNS lesions were observed after chronic treatment with cerivastatin for up to two years in the mouse (up to 6 times human Cmax free drug levels) and rat (in the range of human Cmax free drug levels).
Baycol (cerivastatin) is an HMGCoA reductase inhibitor (a “statin”) that lowers cholesterol in the blood by blocking the enzyme in the liver that is responsible for producing cholesterol. It lowers total cholesterol as well as the LDL subfraction of cholesterol in the blood. Common side effects of Baycol include constipation, diarrhea, fatigue, gas, heartburn, nasal congestion, and headache. It is unknown if Baycol causes harm to the fetus if taken during pregnancy. It is unknown if Baycol is secreted in breast milk.
Multimedia: Slideshows, Images & Quizzes
Cholesterol Levels: What's Normal and How to Lower High Cholesterol
What do cholesterol numbers mean? LDL, HDL, good, bad, and triglycerides - Get the facts on cholesterol, blood testing,...
How to Lower Your Cholesterol & Save Your Heart
Need to lower your cholesterol levels? Use these smart diet tips to quickly and easily lower your blood cholesterol levels....
Cholesterol Drugs: What to Expect With Heart Medication
When diet and exercise aren't enough, should you turn to drugs? Learn cholesterol basics, drug classes, and available drugs along...
High Cholesterol (Hyperlipidemia) Quiz: Test Your Medical IQ
High cholesterol can be a dangerous condition. Take the Cholesterol Quiz to understand what high cholesterol means in terms of...
Picture of Cholesterol
Cholesterol carried in particles of low density (LDL cholesterol) is referred to as the "bad" cholesterol because elevated levels...
Cholesterol: High Triglyceride Foods to Avoid
High triglycerides increase the risk of heart disease. Lower triglyceride levels and reduce cholesterol by eating foods that...
Related Disease Conditions
High cholesterol and triglyceride levels increase the risk of cardiovascular disease. Getting your cholesterol and triglyceride levels in an optimal range will help protect your heart and blood vessels. Cholesterol management may include lifestyle interventions (diet and exercise) as well as medications to get your total cholesterol, LDL, HDL, and triglycerides in an optimal range.
What Are the Normal Cholesterol Levels According to Age?
Cholesterol is a waxy substance found in all the cells of the body. It is a type of fat that is produced by the liver. Cholesterol also comes from animal-derived foods, such as meat and dairy products.
Lower Cholesterol Levels with Diet and Medications
High-density lipoprotein (HDL) cholesterol is considered "good" cholesterol because it actually works to keep the LDL or "bad" cholesterol from building up in your arteries. Foods like extra lean meats, skim milk, and vegetable-based "butter-like" substitutes may help decrease LDL levels in the bloodstream.
What Is the Normal Range for Cholesterol Levels?
What is the normal range for cholesterol levels? Learn what cholesterol levels are, why cholesterol levels change, how doctors diagnose cholesterol levels, and what you can do to treat high cholesterol levels.
HDL vs. LDL Cholesterol (Good and Bad)
HDL (high-density lipoprotein), or the "good" cholesterol, and LDL (low-density lipoprotein), or the "bad" cholesterol, are lipoproteins that carry cholesterol through the veins and arteries of the body. HDL and LDL combined, is your "total" blood cholesterol. The difference between the two are that high levels of the "good," or HDL cholesterol, may protect against narrowing of the blood vessels in the body, which protects you against heart attack, stroke, and other cardiovascular diseases. But high levels of LDL, or the "bad" cholesterol, may worsen the narrowing of the blood vessels in the body, which puts you at a greater risk of stroke, heart attack, and cardiovascular diseases, some of which are life threatening.Triglycerides are found in body fat and from the fats you eat.
What Reduces Cholesterol Quickly?
High blood cholesterol levels can be managed to a great extent with lifestyle changes. However, not taking medicine isn’t a solution because only lifestyle changes may not be sufficient to treat high cholesterol levels.
What Are the Causes of High Cholesterol?
Your body naturally produces all the LDL (bad) cholesterol it needs. An unhealthy lifestyle – not enough exercise, too many unhealthy foods – makes your body produce more LDL cholesterol than it needs. This is the cause of high LDL cholesterol for most people.
What Are the Normal Cholesterol Levels By Age?
Cholesterol is a waxy substance found in all the cells of the body. It is a type of fat that is produced by the liver. Cholesterol also comes from animal-derived foods, such as meat and dairy products. It is an essential substance needed by the body for various purposes. Too much cholesterol, however, harms the body and increases the risk of various medical conditions, such as high blood pressure and heart diseases.
Treatment & Diagnosis
- High Cholesterol (Hyperlipidemia) FAQs
- Statins - - Doing More Than Lowering Your Cholesterol?
- Cholesterol: Questions To Ask Your Doctor
- Cholesterol: The Truth About Cholesterol
- Cholesterol: HDL cholesterol ratio
- Cholesterol - Mr. D.T.'s Story of Hope
- Cholesterol Guidelines for Adults (2001)
- Cholesterol Guidelines
- Heart Attack Prevention From a Doctor's Perspective
- What Should Cholesterol Levels Be After Heart Attack?
- Can Menopause Cause High Cholesterol?
- What are Cholesterol-Lowering Statins?
- Do Bile Acid Resins Lower Cholesterol?
- Can Fibrate Drugs Lower Cholesterol?
- How Do I Lower My Cholesterol (Triglycerides)
- Does Hypothyroidism Cause High Cholesterol?
- Does Exercise Lower Cholesterol?
- What Foods Lower Cholesterol?
- Does Stress Cause High Cholesterol?
- Cholesterol Treatment
- Cholesterol, The Basics Of Prevention
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.